DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Titel:
DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Auteur:
Madurka, Ildiko Vishnevsky, Alexander Soriano, Joan B. Gans, Stephanus J. Ore, Danilo Joel Salazar Rendon, Adrian Ulrik, Charlotte S. Bhatnagar, Sushma Krishnamurthy, Srikanth Mc Harry, Kirsten Welte, Tobias Fernandez, Alberto A. Mehes, Beata Meiser, Karin Gatlik, Ewa Sommer, Ulrike Junge, Guido Rezende, Ederlon ,